# INTERVIEW: Zeus Capital Upgrade forecast for Allergy Therapeutics Plc

- Link: https://www.directorstalkinterviews.com/interview-zeus-capital-upgrade-forecast-allergy-therapeutics-plc/412721960
- Published: 2017-01-23T08:09:56+00:00
- Author: Giles Arbor

**Allergy Therapeutics Plc** ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l))
is the topic of conversation when DirectorsTalk caught up with Dr Gary Waanders 
the Director of Healthcare Research at Zeus Capital. Gary explains whats driven 
growth in the 6 months to Dec 31st, affects on the full year and what other things
should we be focusing on for Allergy Therapeutics.

 

Allergy Therapeutics Plc is an international specialty pharmaceutical company focussed
on the treatment and diagnosis of allergic disorders including immunotherapy vaccines
that cure disease. The Company sells proprietary products and third party products
from its subsidiaries in nine major European countries and via distribution agreements
in an additional ten countries. Formed in 1999 out of Smith Kline Beecham, the comapy
is headquartered in Worthing, UK with MHRA-approved manufacturing facilities. The
Company employs c.495 employees and is listed on the London Stock Exchange (LON:
AGY).  The company had its target price increased by analysts at FinnCap on Thursday
from GBX 40 to GBX 43. The firm currently has a “buy” rating on the stock, however
a number of brokers have issued stock reports with the consensus target price being
64.67 GBX.

Share on:
